AQS Bio becomes the first consulting company to assist with one of the first Global Licensing Agreement expansions, between a Japanese biopharma and a top 15 Chinese biopharma, for a novel clinical stage obesity asset.
AQS Bio becomes the first consulting company to assist with one of the first Global Licensing Agreement expansions, between a Japanese biopharma and a top 15 Chinese biopharma, for a novel clinical stage obesity asset.